Akebia Therapeutics (United States)

Recent papers from Akebia Therapeutics (United States)

1. Tadpole Doctor: a UK-based citizen science project that identifies novel Perkinsea clades closely related to candidate amphibian pathogensISME Communications · 2026
2. A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).Journal of Clinical Oncology · 2026
3. PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME).Journal of Clinical Oncology · 2026
4. Quality of life in cancer patients treated with anchored interleukin-12 (IL-12) immunotherapy: Results from a first-in-human phase 1 trial of tolododekin alfa (ANK-101).Journal of Clinical Oncology · 2026
5. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levelsEuropean Heart Journal · 2019
6. Abstract 1563: Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumorsCancer Research · 2026
7. Abstract 2422: Next-generation chemical biology: Mapping the Purinome druggable space reveals genotype-specific vulnerabilities via phenotypic screeningCancer Research · 2026
8. A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United StatesExpert Opinion on Biological Therapy · 2026
9. Abstract B021: Alum-anchored IL-12 combined with HDAC inhibition overcomes checkpoint blockade refractory tumorsCancer Immunology Research · 2026
10. Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent DoseHemodialysis International · 2025
11. A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysisBMC Nephrology · 2025
12. Identification of HIF1A as a therapeutic target during SARS-CoV-2–associated lung injuryJCI Insight · 2025
13. Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sampleJournal of Affective Disorders · 2025
14. Vascular Access Thrombosis Events in Patients With Dialysis-Dependent CKD Treated With Vadadustat or Darbepoetin Alfa: The INNO2VATE Trial ProgramKidney Medicine · 2025
15. A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid TumorsMolecular Cancer Therapeutics · 2025
16. Detecting deviations from Kingman coalescence using 2-site frequency spectraGenetics · 2025
17. Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant MelanomaMolecular Cancer Therapeutics · 2024
18. Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer modelsJournal for ImmunoTherapy of Cancer · 2024
19. Safety and Efficacy of Vadadustat Once-Daily and 3-Times-Weekly in Dialysis-Dependent Chronic Kidney Disease Patients with AnemiaKidney360 · 2024
20. Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expressionAlzheimer s & Dementia · 2024